Freeflow Ventures is hosting a discussion that will focus on portfolio company Appia Bio on Thursday, September 15th at 8am Pacific / 11am Eastern. You can register here and invite others that might be interested.

Appia Bio discovers and develops off-the-shelf allogeneic cell therapies for cancer patients from healthy donor hematopoietic stem cells. Their breakthrough platform is based on technology initially developed in Nobel Laureate and President Emeritus David Baltimore’s lab at Caltech. Learn more about the company at

The discussion will kick off with a presentation and introductory remarks from CEO and co-founder JJ Kang. It will be followed by Q&A with Freeflow and concluded with questions from the audience.